Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$2.74 - $13.43 $5.22 Million - $25.6 Million
-1,906,557 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$10.24 - $20.87 $7.64 Million - $15.6 Million
-745,996 Reduced 28.12%
1,906,557 $19.5 Million
Q1 2021

May 14, 2021

SELL
$16.9 - $29.77 $561,519 - $989,138
-33,226 Reduced 1.24%
2,652,553 $48.8 Million
Q4 2020

Feb 16, 2021

BUY
$16.48 - $34.3 $277,951 - $578,503
16,866 Added 0.63%
2,685,779 $88.9 Million
Q3 2020

Nov 16, 2020

BUY
$16.02 - $18.46 $42.8 Million - $49.3 Million
2,668,913 New
2,668,913 $45.4 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $24.6M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.